The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia.

Introduction: The impact of amyloid positron emission tomography (PET) imaging on patient health outcomes for individuals with dementia is unknown. In the present study, we explored the association between diagnostic outcome and clinician's level of certainty with quality of life (QoL) after [18F]flutemetamol PET results were disclosed in young onset dementia patients in a memory clinic cohort.

Methods: In 154 patients suspected of dementia, QoL was measured before and after [18F]flutemetamol PET results were disclosed.